Concord Biotech Ltd vs Glenmark Pharmaceuticals Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 06, 2026

Key Highlights

The Latest Trading Price of Concord Biotech Ltd is ₹ 1223 as of 06 May 15:30 . The P/E Ratio of Concord Biotech Ltd changed from 51.7 on March 2024 to 47.2 on March 2025 . This represents a CAGR of -4.45% over 2 yearsThe P/E Ratio of Glenmark Pharmaceuticals Ltd changed from 13.5 on March 2021 to 41.5 on March 2025 . This represents a CAGR of 25.18% over 5 years The Market Cap of Concord Biotech Ltd changed from ₹ 15922 crore on March 2024 to ₹ 17537 crore on March 2025 . This represents a CAGR of 4.95% over 2 yearsThe Market Cap of Glenmark Pharmaceuticals Ltd changed from ₹ 13108 crore on March 2021 to ₹ 43458 crore on March 2025 . This represents a CAGR of 27.09% over 5 years The revenue of Concord Biotech Ltd for the Dec '25 is ₹ 287.74 crore as compare to the Sep '25 revenue of ₹ 262.7 crore. This represent the growth of 9.53% The revenue of Glenmark Pharmaceuticals Ltd for the Dec '25 is ₹ 3945 crore as compare to the Sep '25 revenue of ₹ 6247 crore. This represent the decline of -36.85% The ebitda of Concord Biotech Ltd for the Dec '25 is ₹ 104.98 crore as compare to the Sep '25 ebitda of ₹ 104.13 crore. This represent the growth of 0.82% The ebitda of Glenmark Pharmaceuticals Ltd for the Dec '25 is ₹ 729.88 crore as compare to the Sep '25 ebitda of ₹ 1175 crore. This represent the decline of -37.89% The net profit of Concord Biotech Ltd changed from ₹ 59.59 crore to ₹ 63.64 crore over 7 quarters. This represents a CAGR of 3.83% The net profit of Glenmark Pharmaceuticals Ltd changed from ₹ 340.24 crore to ₹ 403.23 crore over 7 quarters. This represents a CAGR of 10.19% The Dividend Payout of Concord Biotech Ltd changed from 2.73 % on March 2022 to 24.54 % on March 2025 . This represents a CAGR of 73.15% over 4 yearsThe Dividend Payout of Glenmark Pharmaceuticals Ltd changed from 4.28 % on March 2021 to 4.38 % on March 2025 . This represents a CAGR of 0.46% over 5 years .

About Concord Biotech Ltd

Concord Biotech Limited was originally incorporated as Servomed Pharmaceuticals Private Limited' at Ahmedabad, Gujarat as a Private Limited Company dated November 23, 1984, issued by the Registrar of Companies.
Thereafter, name of the Company was changed to Concord Biotech Limited' dated February 16, 2001, which became a Public Company and a fresh Certificate of Incorporation dated November 7, 2001 was issued by the RoC. The Company is an India-based bio pharma and one of the leading global developers and manufacturers of select fermentation-based APIs across immunosuppressants and oncology in terms of market share, based on volume in supplying to over 70 countries including regulated markets, such as the United States, Europe and Japan, and India.
Presently, it is engaged in research and development, manufacturing, marketing and selling of pharmaceutical products.

About Glenmark Pharmaceuticals Ltd

Glenmark Pharmaceuticals Limited was incorporated on November 18, 1977.
The Company is actively involved in the discovery of new molecules both NCEs (new chemical entity) and NBEs (new biological entity).
It is engaged in the business of development, manufacture and marketing of pharmaceutical products both formulation and active pharmaceuticals ingredients to regulated and semi-regulated markets.
The Company's research and development facilities are located at Mahape, Sinnar and Taloja and manufacturing facilities are located at Nasik, Colvale, Baddi, Nalagarh, Sikkim, Indore and Aurangabad in India. The company has several molecules in various stages of pre-clinical and clinical development primarily focused in the areas of Oncology, Respiratory and Dermatology.
Its branded generics business has a significant presence in markets across emerging economies including India.

FAQs for the comparison of Concord Biotech Ltd and Glenmark Pharmaceuticals Ltd

Which company has a larger market capitalization, Concord Biotech Ltd or Glenmark Pharmaceuticals Ltd?

Market cap of Concord Biotech Ltd is 12,795 Cr while Market cap of Glenmark Pharmaceuticals Ltd is 66,987 Cr

What are the key factors driving the stock performance of Concord Biotech Ltd and Glenmark Pharmaceuticals Ltd?

The stock performance of Concord Biotech Ltd and Glenmark Pharmaceuticals Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Concord Biotech Ltd and Glenmark Pharmaceuticals Ltd?

As of May 6, 2026, the Concord Biotech Ltd stock price is INR ₹1223.05. On the other hand, Glenmark Pharmaceuticals Ltd stock price is INR ₹2373.75.

How do dividend payouts of Concord Biotech Ltd and Glenmark Pharmaceuticals Ltd compare?

To compare the dividend payouts of Concord Biotech Ltd and Glenmark Pharmaceuticals Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.